Spotlight on Coronary Microvascular Dysfunction at TCT 2025
November 19, 2025
TCT 2025 | VahatiCor Symposium Recap
For the second time this year, we’ve organized a scientific symposium at a major interventional cardiology conference. We’ve put together an excellent panel to dive deep into Coronary Microvascular Dysfunction.
Speakers and Moderators

Dr. Bruce Samuels

Dr. Amir Lerman

Dr. Odayme Quesada

Dr. Khaled Ziada

Dr. Francesco Giannini

Dr. Samit Shah

Dr. Alexandra Lansky
Interviews with Our TCT Faculty
Ahead of this year’s TCT symposium, we’ve asked our speakers the following:
1.What is the one message you want to communicate?
2. Your thoughts on the upcoming studies with A-FLUX Reducer therapy?
Dr. Odayme Quesada
“We are increasingly recognizing that patients with angina and non obstructive disease have underlying Coronary Microvascular Dysfunction.”
“I am excited for the evidence for the A-FLUX therapy.”
The A-FLUX® Reducer is an investigational device and is not approved for commercial sale. Any discussion of clinical use relates to an investigational context only and is subject to applicable regulations.